CoChat
Sign Up
Cited by 58

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

PCSK9 levels in abdominally obese men: Association with cardiometabolic risk profile and effects of a one-year lifestyle modification program

Arsenault, Benoit J., Pelletier-Beaumont, Emilie, Alméras, Natalie, Tremblay, Angelo, Poirier, Paul, Bergeron, Jean, Després, Jean-Pierre·2014·Atherosclerosis
DOI 10.1016/j.atherosclerosis.2014.07.010
Open this paper in CoChat — free account

Abstract

Objectives Studies performed in rodents have suggested a role for proprotein convertase subtilisin/kexin type 9 (PCSK9) in insulin resistance and impaired body fat distribution. Our objective was to examine the relationships between markers of adiposity and insulin resistance and plasma PCSK9 levels in humans. In addition, we explored the effect of a one-year lifestyle modification program on plasma PCSK9 levels in abdominally obese, dyslipidemic men. Methods Plasma PCSK9 levels were measured by ELISA in 175 abdominally obese, dyslipidemic sedentary men. Of these abdominally obese men, 117 non-diabetic individuals completed a one-year lifestyle modification program aiming at increasing cardiorespiratory fitness levels and improving nutritional quality. Results We found no association between plasma PCSK9 levels and body mass index, waist circumference, fat and fat-free mass, or visceral and subcutaneous adipose tissue measured by computed tomography. Compared to men with the lowest PCSK9 levels (bottom tertile), those with the highest PCSK9 levels (top tertile) had the most detrimental lipoprotein-lipid profile including lower LDL particle size (253.6 ± 4.0 vs. 251.6 ± 4.0 Å, p Conclusions Plasma PCSK9 levels are not associated with body fat distribution indices, modestly associated with markers of insulin resistance and LDL particle size and are slightly affected by a lifestyle modification program in abdominally obese men.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.atherosclerosis.2014.07.010

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Known pathways that regulate post-transcriptional levels of LDLR include PCSK9 and Idol.

    “Known pathways that regulate post-transcriptional levels of LDLR include PCSK9 (pro-protein convertase subtilisin/kexin type 9) and Idol (inducible degrader of the LDLR) (Arsenault et al., 2014; Lakoski et al., 2009; Zelcer et al., 2009)”

    From γ-secretase inhibition lowers plasma triglyceride-rich lipoproteins by stabilizing the LDL receptor (2018) · cites this paper as Arsenault et al., 2014

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 28

  1. Abifadel, 2003, Mutations in PCSK9 cause autosomal dominant hypercholesterolemia, Nat Genet, 34, 154, 10.1038/ng1161 · DOI · Paper page
  2. Nordestgaard, 2013, Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European atherosclerosis society, Eur Heart J, 34, 3478, 10.1093/eurheartj/eht273 · DOI · Paper page
  3. Deloukas, 2013, Large-scale association analysis identifies new risk loci for coronary artery disease, Nat Genet, 45, 25, 10.1038/ng.2480 · DOI · Paper page
  4. Benn, 2010, PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses, J Am Coll Cardiol, 55, 2833, 10.1016/j.jacc.2010.02.044 · DOI
  5. Lagace, 2006, Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice, J Clin Invest, 116, 2995, 10.1172/JCI29383 · DOI · Paper page
  6. Zhang, 2007, Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat a of low density lipoprotein receptor decreases receptor recycling and increases degradation, J Biol Chem, 282, 18602, 10.1074/jbc.M702027200 · DOI · Paper page
  7. Denis, 2012, Gene inactivation of proprotein convertase subtilisin/kexin type 9 reduces atherosclerosis in mice, Circulation, 125, 894, 10.1161/CIRCULATIONAHA.111.057406 · DOI · Paper page
  8. Roubtsova, 2011, Circulating proprotein convertase subtilisin/kexin 9 (pcsk9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue, Arterioscler Thromb Vasc Biol, 31, 785, 10.1161/ATVBAHA.110.220988 · DOI · Paper page
  9. Mbikay, 2010, PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities, FEBS Lett, 584, 701, 10.1016/j.febslet.2009.12.018 · DOI
  10. Langhi, 2009, PCSK9 is expressed in pancreatic delta-cells and does not alter insulin secretion, Biochem Biophys Res Commun, 390, 1288, 10.1016/j.bbrc.2009.10.138 · DOI
  11. Chernogubova, 2012, Common and low-frequency genetic variants in the PCSK9 locus influence circulating PCSK9 levels, Arterioscler Thromb Vasc Biol, 32, 1526, 10.1161/ATVBAHA.111.240549 · DOI
  12. Baass, 2009, Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents, Clin Chem, 55, 1637, 10.1373/clinchem.2009.126987 · DOI
  13. Nazare, 2013, Changes in both global diet quality and physical activity level synergistically reduce visceral adiposity in men with features of metabolic syndrome, J Nutr, 143, 1074
  14. van der Kooy, 1993, Abdominal diameters as indicators of visceral fat: comparison between magnetic resonance imaging and anthropometry, Br J Nutr, 70, 47, 10.1079/BJN19930104 · DOI
  15. Ferland, 1989, Assessment of adipose tissue distribution by computed axial tomography in obese women: association with body density and anthropometric measurements, Br J Nutr, 61, 139, 10.1079/BJN19890104 · DOI
  16. Després, 2009, Effect of rimonabant on the high-triglyceride/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the adagio-lipids trial, Arterioscler Thromb Vasc Biol, 29, 416, 10.1161/ATVBAHA.108.176362 · DOI
  17. Allain, 1974, Enzymatic determination of total serum cholesterol, Clin Chem, 20, 470, 10.1093/clinchem/20.4.470 · DOI
  18. Fossati, 1982, Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide, Clin Chem, 28, 2077, 10.1093/clinchem/28.10.2077 · DOI
  19. Arsenault, 2007, Cholesterol levels in small LDL particles predict the risk of coronary heart disease in the epic-norfolk prospective population study, Eur Heart J, 28, 2770, 10.1093/eurheartj/ehm390 · DOI · Paper page
  20. Pérusse, 2001, A new method for HDL particle sizing by polyacrylamide gradient gel electrophoresis using whole plasma, J Lipid Res, 42, 1331, 10.1016/S0022-2275(20)31585-6 · DOI
  21. Borel, 2013, Improved plasma FFA/insulin homeostasis is independently associated with improved glucose tolerance after a 1-year lifestyle intervention in viscerally obese men, Diabetes Care, 36, 3254, 10.2337/dc12-2353 · DOI
  22. Pelletier-Beaumont, 2012, Normalization of visceral adiposity is required to normalize plasma apolipoprotein B levels in response to a healthy eating/physical activity lifestyle modification program in viscerally obese men, Atherosclerosis, 221, 577, 10.1016/j.atherosclerosis.2012.01.023 · DOI
  23. Kappelle, 2011, Plasma proprotein convertase subtilisin-kexin type 9 does not change during 24h insulin infusion in healthy subjects and type 2 diabetic patients, Atherosclerosis, 214, 432, 10.1016/j.atherosclerosis.2010.10.028 · DOI
  24. Awan, 2013, Regional distribution and metabolic effect of PCSK9 insleu and R46L gene mutations and APOE genotype, Can J Cardiol, 29, 927, 10.1016/j.cjca.2013.03.004 · DOI
  25. Costet, 2006, Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c, J Biol Chem, 281, 6211, 10.1074/jbc.M508582200 · DOI
  26. Arsenault, 2012, Mapping body fat distribution: a key step towards the identification of the vulnerable patient?, Ann Med, 44, 758, 10.3109/07853890.2011.605387 · DOI
  27. Dubuc, 2004, Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia, Arterioscler Thromb Vasc Biol, 24, 1454, 10.1161/01.ATV.0000134621.14315.43 · DOI · Paper page
  28. Borel, 2012, Visceral and not subcutaneous abdominal adiposity reduction drives the benefits of a 1-year lifestyle modification program, Obes (Silver Spring), 20, 1223, 10.1038/oby.2011.396 · DOI

Cited by

Sorted by citations

Metadata

Authors
Arsenault, B. J., Pelletier-Beaumont, E., Alméras, N., Tremblay, A., Poirier, P., Bergeron, J., & Després, J.-P.
Venue
Atherosclerosis
Publisher
Elsevier BV
Published
2014-10
Volume
236
Issue
2
Pages
321-326
ISSN
0021-9150
DOI
10.1016/j.atherosclerosis.2014.07.010
Cited by
58
References
3
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Funders
Canadian Institutes of Health Research (MOP-64439)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review